1. Brand R, et al. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer 124, 3520-3527 (2018).
2. Li JT, et al. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Nat Cell Biol 22, 167-174 (2020).
3. Biffi G, et al. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discov 9, 282-301 (2019).
4. Principe DR, et al. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy. Cancer Res 80, 3101-3115 (2020).
5. Wang Y, et al. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Clin Cancer Res 26, 5462-5476 (2020).
6. Costa-Silva B, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 17, 816-826 (2015).
7. Sehdev A, et al. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Clin Cancer Res 24, 6204-6211 (2018).
8. Asher G, et al. Poly(ADP-ribose) polymerase 1 participates in the phase entrainment of circadian clocks to feeding. Cell 142, 943-953 (2010).
9. Seufferlein T & Mayerle J. Pancreatic cancer in 2015: Precision medicine in pancreatic cancer--fact or fiction? Nat Rev Gastroenterol Hepatol 13, 74-75 (2016).
10. Bryant HE, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
11. Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
12. Kaufman B, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33, 244-250 (2015).
13. Rouleau M, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10, 293-301 (2010).
14. Golan T, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 381, 317-327 (2019).
15. Yurgelun MB, et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med 21, 213-223 (2019).
16. Ryan DP, Hong TS & Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 371, 1039-1049 (2014).
17. Jachimowicz RD, et al. UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. Cell 176, 505-519 (2019).
18. Barber LJ, et al. RTEL1 maintains genomic stability by suppressing homologous recombination. Cell 135, 261-271 (2008).
19. Bai Y, et al. C1QBP Promotes Homologous Recombination by Stabilizing MRE11 and Controlling the Assembly and Activation of MRE11/RAD50/NBS1 Complex. Mol Cell 75, 1299-1314 (2019).
20. Wang Q, et al. Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular response to DNA double-strand breaks. EMBO J 33, 862-877 (2014).
21. Kanakkanthara A, et al. ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer. Nat Commun 10, 4632-4636 (2019).
22. He YJ, et al. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature 563, 522-526 (2018).
23. Stracker TH & Petrini JH. The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol 12, 90-103 (2011).
24. Hopfner KP, et al. Structural biochemistry and interaction architecture of the DNA double-strand break repair Mre11 nuclease and Rad50-ATPase. Cell 105, 473-485 (2001).
25. Lobachev KS, Gordenin DA & Resnick MA. The Mre11 complex is required for repair of hairpin-capped double-strand breaks and prevention of chromosome rearrangements. Cell 108, 183-193 (2002).
26. Buis J, et al. Mre11 nuclease activity has essential roles in DNA repair and genomic stability distinct from ATM activation. Cell 135, 85-96 (2008).
27. Li Z, et al. Plk1 phosphorylation of Mre11 antagonizes the DNA damage response. Cancer Research 77, 3169-3180 (2017).
28. Jachimowicz RD, et al. UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors. Cell 176, 505-519 (2019).
29. Bai Y, et al. C1QBP Promotes Homologous Recombination by Stabilizing MRE11 and Controlling the Assembly and Activation of MRE11/RAD50/NBS1 Complex. Mol Cell 75, 1299-1314 (2019).
30. He YJ, et al. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature 563, 522-526 (2018).
31. Liu J, et al. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat cell biol 20, 1074-1083 (2018).
32. Barranco C. Viral infection linked to m 6 A alterations in host mRNAs. Nat Rev Mol Cell Biol 21, 64-65 (2020).
33. Lin S & Gregory RI. Methyltransferases modulate RNA stability in embryonic stem cells. Nat cell biol 16, 129-131 (2014).
34. Xiang Y, et al. RNA m 6 A methylation regulates the ultraviolet-induced DNA damage response. Nature 543, 573-576 (2017).
35. Zhang C, et al. METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DSBs by Modulating DNA-RNA Hybrid Accumulation. Mol Cell 79, 425-442 (2020).
36. Kleger A, Perkhofer L & Seufferlein T. Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol 25, 1260-1270 (2014).
37. Helms E, Onate MK & Sherman MH. Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment. Cancer Discov 10, 648-656 (2020).
38. Perkhofer L, et al. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Cancer Res 77, 5576-5590 (2017).
39. Nowsheen S, et al. L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20, 455-464 (2018).
40. Mukherjee B, Tomimatsu N & Burma S. Immunofluorescence-based methods to monitor DNA end resection. Methods Mol Biol 1292, 67-75 (2015).
41. D'Amours D & Jackson SP. The Mre11 complex: at the crossroads of dna repair and checkpoint signalling. Nat Rev Mol Cell Biol 3, 317-327 (2002).
42. Williams RS, et al. Mre11 dimers coordinate DNA end bridging and nuclease processing in double-strand-break repair. Cell 135, 97-109 (2008).
43. Mendel M, et al. Methylation of structured RNA by the m6A writer METTL16 is essential for mouse embryonic development. Mol cell 71, 986-1000 (2018).
44. Pendleton KE, et al. The U6 snRNA m6A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell 169, 824-835 (2017).
45. Doxtader KA, et al. Structural basis for regulation of METTL16, an S-adenosylmethionine homeostasis factor. Mol cell 71, 1001-1011 (2018).
46. Golan T, et al. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. Int J Cancer 143, 179-183 (2018).
47. Perkhofer L, et al. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut 70, 606-617 (2021).
48. Humpton TJ, et al. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. Cancer Discov 9, 1268-1287 (2019).
49. Huertas P, et al. CDK targets Sae2 to control DNA-end resection and homologous recombination. Nature 455, 689-692 (2008).
50. Broderick R, et al. EXD2 promotes homologous recombination by facilitating DNA end resection. Nat Cell Biol 18, 271-280 (2016).
51. Zhao F, et al. DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells. Exp Mol Med 52, 1705-1714 (2020).
52. Rodrigues G, et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol 21, 1403-1412 (2019).
53. Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol 13, 4 (2020).
54. Zhang Y, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 20, 1181-1192 (2018).
55. Parvin S, et al. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL. Cancer Cell 36, 237-249 (2019).
56. Yuan J, et al. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140, 384-396 (2010).
57. Barnes C & Kanhere A. Identification of RNA-Protein Interactions Through In Vitro RNA Pull-Down Assays. Methods Mol Biol 1480, 99-113 (2016).
58. Güntert P. Automated NMR structure calculation with CYANA. Methods Mol Biol 278, 353-378 (2004).
59. Raveh B, et al. Rosetta FlexPepDock ab-initio: simultaneous folding, docking and refinement of peptides onto their receptors. PLoS One 6, e18934 (2011).
60. Huang J & MacKerell AD. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J Comput Chem 34, 2135-2145 (2013).
61. Bussi G, Donadio D & Parrinello M. Canonical sampling through velocity rescaling. J Chem Phys 126, 014101 (2007).
62. Linse B & Linse P. Tuning the smooth particle mesh Ewald sum: application on ionic solutions and dipolar fluids. J Chem Phys 141, 184114 (2014).
63. Hess B. P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation. J Chem Theory Comput 4, 116-122 (2008).
64. Liu T, et al. A divergent role of the SIRT1-TopBP1 axis in regulating metabolic checkpoint and DNA damage checkpoint. Mol Cell 56, 681-695 (2014).
65. Yan Y, et al. The deubiquitinase USP36 Regulates DNA replication stress and confers therapeutic resistance through PrimPol stabilization. Nucleic Acids Res 48, 12711-12726 (2020).